ENDURA-2

• Research type

  Research Study

• Full title

  A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

• IRAS ID

  1012603

• Contact name

  Ashutosh Mishra

• Contact email

  ashutosh.3.mishra@gsk.com

• Sponsor organisation

  GlaxoSmithKline Research & Development Ltd

• Clinicaltrials.gov Identifier

  NCT06959095

• Research summary

  This is randomised, double blind, placebo-controlled, multicentre study of the efficacy and safety of a medication called depemokimb in adults with COPD with type 2 inflammation.
  Randomised means participant (ppt)s do not know if they will receive depemokimb or placebo (no medication). Double blind means neither the ppt nor the study doctor will know if the ppt receives placebo or depemokimb.
  COPD is a lung condition characterised by chronic respiratory symptoms (such as, cough, sputum production) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.
  The immune system has different ways to responding to threats, type 1 and type 2. Type 1 response is primarily geared towards eliminating pathogens, such as bacteria and pathogens. Type 2 combats larger threats. This pathway stimulates antibody production. Type 2 inflammatory response is orchestrated by messenger proteins called interleukins (ILs). One of the interleukins important in driving the type 2 response is IL5.

  Depemokimab is a type of medication known as a ‘biologic’, it is an injectable anti-IL5 therapy. Reducing the type 2 response may reduce airway inflammation and aid COPD symptoms.

  This study is being done to test if depemokimab can improve COPD.

  Approximately 960 people will take part in this study. The study duration is approx 1 year and 3 months, up to a maximum of about 2 years and 3 months for each participant.
  Taking part includes taking part in the following: ECGs, breathing tests, blood samples, nasal brushing, CT scan/ X-ray and completion of questionnaires and diaries.

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  25/EM/0241

• Date of REC Opinion

  20 Jan 2026

• REC opinion

  Further Information Favourable Opinion